| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
The biological effects of 15-Keto-PGA1 are mediated through its interaction with multiple targets. It has been designated as targeting the Angiotensin Receptor. Additionally, it prevents the conversion of arachidonic acid to prostacyclin by inhibiting the enzyme cyclooxygenase (COX). It is also involved in modulating the activity of prostaglandins through interaction with 15-hydroxyprostaglandin dehydrogenase (15-PGDH), the enzyme that produces it.
|
|---|---|
| ln Vitro |
The primary in vitro characteristic of 15-Keto-PGA1 is its capacity as a vasoconstrictor. In isolated blood vessel preparations, it has demonstrated potent vasoconstrictor effects. It is formed by the action of 15-hydroxyprostaglandin dehydrogenase on PGA1, which itself is a vasoconstrictor. Its role in inhibiting cyclooxygenase (COX) suggests it can modulate the production of other prostaglandins and related lipid mediators.
|
| ln Vivo |
No specific in vivo studies for 15-Keto-PGA1 were found in the available literature. As a metabolite of PGA1, its vasoconstrictor actions are inferred from the known activity of its parent compound, PGA1. PGA1 is a more potent vasoconstrictor than PGF2alpha and angiotensin II. 15-Keto-PGA1 is therefore thought to contribute to the overall vascular effects of endogenous prostaglandin metabolism, particularly in the kidney.
|
| Enzyme Assay |
A standard protocol for studying COX inhibition: COX-1 and COX-2 enzyme assays are performed using a fluorometric kit. The test compound is pre-incubated with the enzyme for 10 minutes. The reaction is initiated by adding arachidonic acid substrate. After 2 minutes, the reaction is stopped, and the fluorescent product (excitation 530 nm, emission 585 nm) is measured. The percent inhibition is calculated relative to a control containing no inhibitor.
|
| Cell Assay |
A standard procedure for testing vasoconstriction involves using isolated rat aortic rings. Following sacrifice, the thoracic aorta is removed and cut into 3-5 mm rings. The rings are mounted in organ chambers filled with Krebs-Henseleit solution (37degC, 95% O2/5% CO2), under 2g resting tension. Isometric tension is recorded. After equilibration, the tissue is pre-contracted with KCl, then cumulative concentrations of 15-Keto-PGA1 (0.1 nM to 10 uM) are added.
|
| Animal Protocol |
No specific in vivo animal protocols were found for 15-Keto-PGA1. A typical in vivo experiment to evaluate vasoactive compounds: In a rat model, compounds are administered intravenously (e.g., via the jugular vein) to anesthetized animals. Blood pressure (systolic, diastolic, and mean) and heart rate are continuously monitored via a catheter inserted into the carotid artery. Responses to 15-Keto-PGA1 (e.g., 0.1-100 ug/kg) are recorded for 30-60 minutes post-administration.
|
| ADME/Pharmacokinetics |
No pharmacokinetic data was found for 15-Keto-PGA1. As a prostaglandin metabolite, its half-life in the circulation is expected to be very short (on the order of seconds to minutes), similar to other eicosanoids. It is produced locally in tissues and is rapidly metabolized or eliminated. Standard PK studies would involve IV administration of the radiolabeled compound to rodents, followed by serial blood sampling and analysis by radioimmunoassay or LC-MS/MS.
|
| Toxicity/Toxicokinetics |
No toxicity data was found for 15-Keto-PGA1. As an endogenous lipid mediator, it is not associated with significant toxicity when produced naturally in the body. For research use, standard laboratory safety precautions should be followed. Given its potent vasoconstrictor properties, it could cause significant cardiovascular effects if administered systemically in vivo.
|
| References | |
| Additional Infomation |
15-Dehydroprostaglandin A1 is a member of the prostaglandin A class of compounds, obtained by oxidizing the 15-hydroxyl group of prostaglandin A1 to the corresponding ketone. It is a metabolite in both *E. coli* and humans. Functionally, it is related to prostaglandin A1. It is the conjugate acid of 15-dehydroprostaglandin A1(1-).
15-Keto-PGA1 is a research-grade biochemical, supplied for laboratory use only, not for human diagnostic or therapeutic applications. Its molecular formula is C20H30O4 and molecular weight 334.45. It is a member of the prostaglandin family and is used to study prostaglandin metabolism, cyclooxygenase inhibition, and vascular regulation. It is a stable, non-enzymatic degradation product derived from its parent prostaglandin. Each product in one row, fields tab-separated. |
| Molecular Formula |
C20H30O4
|
|---|---|
| Molecular Weight |
334.45
|
| Exact Mass |
334.214
|
| CAS # |
61600-67-7
|
| PubChem CID |
90659869
|
| Appearance |
Typically exists as solids at room temperature
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
514.8±50.0 °C at 760 mmHg
|
| Flash Point |
279.2±26.6 °C
|
| Vapour Pressure |
0.0±2.9 mmHg at 25°C
|
| Index of Refraction |
1.533
|
| LogP |
3.33
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
24
|
| Complexity |
476
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CCCCCC(=O)/C=C/[C@H]1C=CC(=O)[C@@H]1CCCCCCC(=O)O
|
| InChi Key |
YKXHFAJZOFTAOC-DTXSUPOZSA-N
|
| InChi Code |
InChI=1S/C20H30O4/c1-2-3-6-9-17(21)14-12-16-13-15-19(22)18(16)10-7-4-5-8-11-20(23)24/h12-16,18H,2-11H2,1H3,(H,23,24)/b14-12+/t16-,18+/m0/s1
|
| Chemical Name |
7-[(1R,5S)-2-oxo-5-[(E)-3-oxooct-1-enyl]cyclopent-3-en-1-yl]heptanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9900 mL | 14.9499 mL | 29.8998 mL | |
| 5 mM | 0.5980 mL | 2.9900 mL | 5.9800 mL | |
| 10 mM | 0.2990 mL | 1.4950 mL | 2.9900 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
